in a funding round led by Cigna Ventures, which looks to utilize GNS' machine learning tech to bring personalized predictive care to Cigna's 86 million customers, per FierceHealthcare.
For payers like Cigna, predictive precision medicine is the holy grail for cutting costs. Precision medicine like GNS' offering could lead to remarkable savings by allowing health plans to"confidently make interventionFor example, the tech could allow clinicians to experiment with drug delivery — testing via simulation which medications their patient would best respond to and cut down on theBut I have reservations about whether GNS can deliver on its lofty claims.
For its simulations to assess whether a patient will respond better to treatment A or treatment B without analyzing documented real-world outcomes — as is the norm — GNS would likely need to model not only the targeted disease, but also how every other relevant health factor interacts with that disease.
There are two major hurdles that could hamper precision medicine firms from delivering clinical improvements: